Home-LaNova Medicines

Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

  • a1_ban1(4)-737.jpg a1_ban1_ph.jpg
    Our Mission
    Care for Life, Dedicate to Innovation
  • a1_ban2-new.jpg ph_ban2-55.jpg
    Our Vision
    Develop High Quality Medicines to Meet Medical Needs of Patients
  • a1_ban3.jpg a1_ban3_ph.jpg
    Our Core Values
    Excellence, Persistence, Integrity, Collaboration
a1_img1.png

Who we are

Rooted in China, innovate for Global

Established since 2019 in Shanghai, China, LaNova Medicines has emerged as a clinical-stage biotechnology company committed to discovering and developing innovative biologic drugs that transform cancer treatments. Our leadership team, composed of experienced industry experts with an unwavering passion for innovation, drives our R&D prowess to deliver transformative therapies for the unmet medical needs of cancer patients.

Harnessing our state-of-the-art technology platforms and deep insight of the tumor microenvironment, we have meticulously crafted a differentiated product pipeline. At LaNova Medicines, we work tirelessly to advance our programs into the clinical domain, with the goal of redefining the treatment landscape of life-threatening diseases.

Our Science

Robust R&D platforms and proprietary technologies

LaNova Medicines specializes in antibody discovery, particularly focusing on multi-transmembrane protein targets like GPCRs. Our R&D team has vast expertise covering target validation, antibody engineering, biologics production, translational studies and clinical development. Leveraging our deep knowledge in antibody discovery, we have built robust R&D platforms to fuel innovation and position us at the forefront of biotech advancements.


Pipeline

Innovative programs targeting the tumor microenvironment

At LaNova, we adopt a comprehensive approach to tackle the complex challenges inherent in cancer treatment. Harnessing the power of our R&D platforms, we have devised a diverse array of therapeutics with varied targets and modalities, effectively influencing the tumor microenvironment. Our robust pipeline encompasses both clinical and preclinical stage programs, addressing a wide range of high-value indications in solid tumors and hematological malignancies. 

We take immense pride in the unique differentiation and exclusive intellectual property rights of our internally discovered, trailblazing programs. Our unwavering dedication to innovation and excellence propels us forward in our quest to transform the therapeutic landscape and improve the lives of those affected by cancer.


Clinical Stage Programs
Program
MOA
Indications
IND
Phase I
Phase II
Phase III
Rights
LM-302
Anti-Claudin18.2 ADC
3L+ GC/GEJ
Global available
LM-302
Anti-Claudin18.2 ADC
1L GC/GEJ
Global available
LM-302
Anti-Claudin18.2 ADC
PDAC
Global available
LM-108
Anti-CCR8 mAb
MSI-H tumors
ex-China available
LM-108
Anti-CCR8 mAb
2L GC/GEJ
ex-China available
LM-101
Anti-SIRPα mAb
Solid tumors & hematologic malignancies
Global available
LM-305
Anti-GPRC5D ADC
Multiple Myeloma
AstraZeneca (Global)
LM-24C5
CEACAM5 BsAb
CRC, GI cancer, lung cancer
Global available
LM-299
anti-PD-1 x anti-VEGF BsAb
Solid tumors
MSD (Global)
LM-168
Anti-CTLA4 (TME specific)
Solid tumors
Global available
LM-2417
Anti-NaPi2b BsAb
Lung cancer, ovarian cancer
Global available
LM-302
3L+ GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-302
1L GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-302
PDAC
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-108
MSI-H tumors
IND
Phase I
Phase II
Phase III
MOA
Anti-CCR8 mAb
Rights
ex-China available
LM-108
2L GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-CCR8 mAb
Rights
ex-China available
LM-101
Solid tumors & hematologic malignancies
IND
Phase I
Phase II
Phase III
MOA
Anti-SIRPα mAb
Rights
Global available
LM-305
Multiple Myeloma
IND
Phase I
Phase II
Phase III
MOA
Anti-GPRC5D ADC
Rights
AstraZeneca (Global)
LM-24C5
CRC, GI cancer, lung cancer
IND
Phase I
Phase II
Phase III
MOA
CEACAM5 BsAb
Rights
Global available
LM-299
Solid tumors
IND
Phase I
Phase II
Phase III
MOA
anti-PD-1 x anti-VEGF BsAb
Rights
MSD (Global)
LM-168
Solid tumors
IND
Phase I
Phase II
Phase III
MOA
Anti-CTLA4 (TME specific)
Rights
Global available
LM-2417
Lung cancer, ovarian cancer
IND
Phase I
Phase II
Phase III
MOA
Anti-NaPi2b BsAb
Rights
Global available
Preclinical Stage Programs
Program
MOA
Indications
Discovery
PCC
IND-enabling
Rights
LM-350
anti-CDH17 ADC
CRC, PDAC, GC
Global available
LM-364
Undisclosed ADC
NSCLC, HNSCC, UC
Global available
LM-338
Undisclosed ADC
CRC, NSCLC, GC
Global available
LM-359
Undisclosed ADC
HCC
Global available
LM-319
Undisclosed ADC
TNBC, lung cancer
Global available
LM-316
Undisclosed ADC
NSCLC, OC, TNBC
Global available
LM-339
Undisclosed ADC
NSCLC, OC
Global available
LM-2199
Undisclosed BsAb
NSCLC, CRC, HNSCC, GC
Global available
LM-350
CRC, PDAC, GC
Discovery
PCC
IND-enabling
MOA
anti-CDH17 ADC
Rights
Global available
LM-364
NSCLC, HNSCC, UC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-338
CRC, NSCLC, GC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-359
HCC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-319
TNBC, lung cancer
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-316
NSCLC, OC, TNBC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-339
NSCLC, OC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-2199
NSCLC, CRC, HNSCC, GC
Discovery
PCC
IND-enabling
MOA
Undisclosed BsAb
Rights
Global available

Partnerships

Creating long-lasting strategic alliances for innovation

Innovation and collaboration lie at the heart of LaNova’s guiding principles. We enthusiastically invite partners who share our vision to engage in product- or technology-focused collaborations with us. We are flexible with different collaboration models, including out-license, in-license, co-development, etc.. Our objective is to cultivate fruitful partnerships that capitalize on the distinct expertise of each party and fully realize the potential of our innovative products. 

  • weibiaoti-4-42.jpg
  • weibiaoti-2-222.jpg
  • a1_img6-267.jpg
  • weibiaoti-3-187.jpg
  • weibiaoti-4.jpg
  • a1_img8.jpg
  • a1_img6-267.jpg

Join Us

To deliver transformative therapeutics for cancer patients